This complaint was first surfaced by Law.com Radar, ALM's source for immediate alerting on just-filed cases in state and ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this ...

This policy applies to all staff, faculty, and relevant personnel at Colorado College (CC) regarding the acquisition, storage, training, and use of epinephrine auto-injectors in response to Colorado ...

Commissions do not affect our editors' opinions or evaluations. We like Auto-Owners’ range of coverage offerings, which include an optional diminishing deductible that reduces your policy ...

The FDA has approved Eli Lilly’s Omvoh (mirikizumab-mrkz ... After dosing, patients received a maintenance dose of 300 mg by subcutaneous injection at week 12 and every four weeks afterwards for a ...

Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn's disease, an inflammatory bowel disease that causes chronic abdominal pain.

Eli Lilly (LLY) announced that the FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of ...

Eli Lilly (NYSE: LLY) is the most valuable healthcare stock in the world, with a market capitalization of around $720 billion. For a while, it looked like it might be on track to be the first ...

Eli Lilly announced preliminary fourth-quarter revenue of roughly $13.5 billion, or $400 million below the low end of its guidance, driven by slower-than-expected US market growth and lower ...